Cargando…
Combination Immunotherapy Use and Withdrawal in Pediatric Inflammatory Bowel Disease—A Review of the Evidence
Evidence-based guidelines have been developed outlining the concomitant use of anti-tumor necrosis factor alpha (anti-TNF) agents and immunomodulators including azathioprine (AZA) and methotrexate (MTX) in both adult and pediatric populations. However, there exists a paucity of data guiding evidence...
Autores principales: | Meredith, Joseph, Henderson, Paul, Wilson, David C., Russell, Richard K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490777/ https://www.ncbi.nlm.nih.gov/pubmed/34621712 http://dx.doi.org/10.3389/fped.2021.708310 |
Ejemplares similares
-
Adalimumab in Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2022) -
Pancreatic Involvement in Pediatric Inflammatory Bowel Disease
por: Martín-de-Carpi, Javier, et al.
Publicado: (2017) -
Cancer Risk in Pediatric-Onset Inflammatory Bowel Disease
por: El-Matary, Wael, et al.
Publicado: (2020) -
Editorial: Pediatric Inflammatory Bowel Diseases: Looking to the Future
por: Wine, Eytan, et al.
Publicado: (2020) -
Gut Microbiota Profile in Pediatric Patients With Inflammatory Bowel Disease: A Systematic Review
por: Zhuang, Xiaojun, et al.
Publicado: (2021)